Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies

NCT05869669 is registered in ClinicalTrials.gov with EIP Pharma Inc as lead sponsor.

NCT NCT05869669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05869669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies
Lead sponsor
EIP Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
May 1, 2023
Completion date
June 16, 2025
Enrollment
159 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

dementia with lewy bodies